Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis

被引:0
作者
David L. Leverenz
Amanda M. Eudy
Malithi Jayasundara
Tayseer Haroun
Gary McDaniel
W. Benjamin Nowell
Jeffrey R. Curtis
Rachelle Crow-Hercher
Whitney White
Seth Ginsberg
Megan E. B. Clowse
机构
[1] Duke University Medical Center (DUMC),Division of Rheumatology & Immunology
[2] Global Healthy Living Foundation,Division of Clinical Immunology and Rheumatology
[3] CreakyJoints,Department of Pharmacy Practice
[4] The University of Alabama at Birmingham,undefined
[5] University of Mississippi,undefined
来源
Clinical Rheumatology | 2019年 / 38卷
关键词
Contraception; Fertility; Psoriatic arthritis; Rheumatoid arthritis;
D O I
暂无
中图分类号
学科分类号
摘要
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are common in women of childbearing age and are often treated with teratogenic medications. In this study, we assessed contraceptive methods in young women with RA or PsA and correlated contraceptive method efficacy with use of concomitant rheumatic medications. We combined the data from several cross-sectional surveys of women under the age of 40 with RA or PsA. Two surveys recruited participants from a clinic setting (RA and PsA Clinic Surveys), and the third survey recruited participants from CreakyJoints.org, an online forum for patients with inflammatory arthritis (CreakyJoints Survey). Of the 164 women included, 138 had RA (67 in RA Clinic Survey, 71 in CreakyJoints Survey) and 26 had PsA (19 in PsA Clinic Survey, 7 in CreakyJoints Survey). Use of specific contraceptive and rheumatic medications were similar between the clinic and online surveys. In the pooled analysis of the Clinic and CreakyJoints survey data, women with RA and PsA reported similar utilization of highly effective contraception methods (31.9% RA, 34.6% PsA) and effective methods (31.2% RA, 30.8% PsA), but different utilization of ineffective methods (35.5% RA, 11.5% PsA) and no methods (1.5% RA, 23.1% PsA), p = 0.0002. These proportions remained similar across subgroups taking methotrexate, anti-TNF biologics, and novel medications. Approximately two thirds of women with RA and PsA reported using effective or highly effective methods of contraception, though women with PsA were more likely to report no methods of contraception.
引用
收藏
页码:1207 / 1212
页数:5
相关论文
共 117 条
  • [1] Weber-Schoendorfer C(2014)Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study Arthritis Rheumatol 66 1101-1110
  • [2] Chambers C(2017)EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome Ann Rheum Dis 76 476-485
  • [3] Wacker E(2014)Contraception and pregnancy counselling in rheumatoid arthritis Curr Opin Rheumatol 26 302-307
  • [4] Beghin D(2010)Managing contraception and pregnancy in the rheumatologic diseases Best Pract Res Clin Rheumatol 24 373-385
  • [5] Bernard N(2015)State of the art: reproduction and pregnancy in rheumatic diseases Autoimmun Rev 14 376-386
  • [6] Shechtman S(2007)Therapy with immunosuppressive drugs and biological agents and use of contraception in patients with rheumatic disease J Rheumatol 34 1266-1269
  • [7] Johnson D(2015)Contraceptive use in women with rheumatologic disease taking disease modifying anti-rheumatic drugs Intern Med J 45 44-657
  • [8] Cuppers-Maarschalkerweerd B(2014)Comparing female-based contraceptive methods in patients with systemic lupus erythematosus, rheumatoid arthritis and a healthy population Int J Rheum Dis 17 653-2147
  • [9] Pistelli A(2018)Increasing contraception use among women receiving teratogenic medications in a rheumatology clinic BMJ Open Quality 7 e000269-827
  • [10] Clementi M(2008)RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories J Rheumatol 35 2136-1205